Your session is about to expire
← Back to Search
Relistor Injection for Chronic Pain in HIV
Study Summary
This trial will test if decreased release of opioids by immune cells contributes to hypersensitivity in HIV patients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a serious mental illness that needed hospital treatment or have been thinking about hurting yourself.I do not have high blood pressure or heart/blood vessel diseases.I have a neurological condition like Parkinson's, MS, or epilepsy.I am HIV negative and either experience pain more than once a week for 3 months or have little to no pain.I am living with HIV and am on a stable ART regimen.I do not have conditions like rheumatoid arthritis or lupus, and I am not experiencing severe weight loss or frailty.I am between 19 and 65 years old.My diabetes is not well-managed (HbA1c over 8%).I am not on conflicting medications, except for stable pain or addiction management.I am HIV positive and a patient at the UAB 1917 Clinic.I have anemia.I have a history of blood disorders that could increase cell breakdown.I do not have any active infections that could affect my blood's immune cells.I have had major surgery within the last year.You have trouble understanding the study procedures because of problems with memory or thinking.
- Group 1: HIV positive with chronic widespread pain
- Group 2: HIV negative with chronic widespread pain
- Group 3: HIV positive without chronic widespread pain
- Group 4: HIV negative without chronic widespread pain
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the participant cap for this clinical experiment?
"Indeed, clinicaltrials.gov states that this experimental medical trial is still searching for participants after it was first published on November 15th 2021 and the last time it was amended being 4th of November 2022. 200 participants have to be found at a solitary site."
Are there any documented precedents of Relistor Injectable Product being trialed in a clinical setting?
"Currently, 3 clinical trials are being carried out to evaluate the effectiveness of Relistor Injectable Product. One is in Phase 3 and its sites are scattered across 6 locations with Birmingham, Alabama as the primary one."
Does this medical trial offer enrollment to individuals who are older than 25?
"This medical trial is only open to adults between 19 and 65 years of age. There are 34 trials for minors and 366 studies recruiting seniors."
Would I meet the criteria to participate in this research study?
"Eligible patients should suffer from chronic pain, be between 19 and 65 years old, and a total of 200 participants shall be included in the medical trial."
Are there any open opportunities to participate in this research?
"Affirmative. The details posted on clinicaltrials.gov demonstrate that this medical trial, which was released on November 15th 2021, is still recruiting participants. A total of 200 individuals are being sought from one centre."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger